Latest News

July 10, 2020
This week, the top managed care news included CMS planning to pay more for at-home dialysis equipment; ACR supports continued use of telemedicine after the COVID-19 pandemic passes; AJMC®’s coverage of AIDS 2020, the 23rd International AIDS Conference.
July 10, 2020
Scientists do not yet have a full understanding of how multiple myeloma develops, but a new article suggests the gut microbiome is one factor that may play a role.
July 10, 2020
In patients with Parkinson disease (PD) who underwent deep brain stimulation, dementia prevalence and incidence were not found to be higher than those in the general PD population, according to study findings.
July 10, 2020
A new study suggests that people living with multiple sclerosis (MS) are often concerned about the costs of their care, but they do not always raise the concern with their doctor.
July 10, 2020
Investigators used death certificate data to determine the annual average decline of deaths attributed to systemic sclerosis.
July 10, 2020
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
July 10, 2020
Twenty pharmaceutical companies created a $1 billion fund to aid financially strained antibiotic development start-ups; the World Health Organization (WHO) concedes that coronavirus disease 2019 (COVID-19) can become airborne; the WHO will launch an independent review into the global pandemic response after the United States formally withdrew from the organization. 
July 10, 2020
Polygenic risk scores, which evaluate disease risk based on DNA variants, have previously been based almost entirely on patients who had European ancestry.
July 09, 2020
Companion diagnostic testing identifies patients most likely to benefit from biomarker-driven treatments. Much of the promise in lung cancer treatment comes from use of testing to match patients with targeted therapies, checkpoint inhibitors, or combinations.
July 09, 2020
Treatment options for psoriatic arthritis and axial spondyloarthritis are increasing, and with studies already identifying response predictors for tumor necrosis factor inhibitors, there is a need to predict response to the interleukin-17A inhibitor secukinumab.
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.